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different methods of mobilization or if long term transplant
outcomes are impacted.Table 1
N Censored 1 yr
survival
rate (%)
3 yr
survival
rate (%)
5 yr
survival
rate (%)
Median
(months)
95% CL
(months)
PFS 29 18 78 68 41 44.7 (17.3, NA)
OS-HSCT 29 20 81 66 66 112.0 (13.9, NA)
OS-DX 29 20 89 66 66 117.2 (18.7, NA)144
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The hematopoietic cell transplantation speciﬁc comorbidity
index (HCT-CI) has been proven to be a valuable tool in
allogeneic stem cell transplant (ASCT) recipients to predict
overall survival. There are few studies that use the HCT-CI for
evaluating autologous stem cell transplantation. Our insti-
tution performs autologous stem cell transplants in a variety
of settings, from completing the whole transplant process
inpatient to instituting their preparative regimen through
transplant and engraftment in the outpatient setting. We
retrospectively reviewed our experience of 250 autologous
stem cell transplants who had a diagnosis that included
Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's
Lymphoma, and Testicular Carcinoma that were either
treated inpatient for their hospital course or were prepared
in the outpatient setting and/or were discharged very early
in their transplant course (day-1 or within three days of their
autologous transplant). The median age of the inpatient
transplant group was 63.5 compared to the outpatient group
that was 58, P< 0.006. The average comorbidity index for the
inpatient group was 2.086 compared to the outpatient group
1.23, P < 0.001. In conclusion, our institution, using the HCT-
CI and age for autologous stem cell transplantation helps to
identify those candidates that are more successfully treated
in the inpatient setting and the outpatient setting. This study
was limited by its retrospective nature, small size and single
center experience. Prospective randomized studies are
needed to determine whether or not the HCT-CI in autolo-
gous stem cell transplantation is truly effective.145
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Background: There is no current standard of care for
patients with newly diagnosed AL amyloidosis. Autologous
HSCT is a potential option, but has been limited in its use due
to increasd treatment-relatedmortality (TRM) (38% from onerandomized study). Two large retrospective analyses showed
improved overall survival (OS) (70% at 4 yrs and 47% at 5 yrs)
of AL amyloid patients undergoing aHSCT compared to
control (40% at 4 yrs) with TRM of 13%.
Methods: We retrospectively analyzed the outcomes of 29
newly diagnosed AL amyloidosis patients who underwent
aHSCT between 10/1998 and 5/2012. Hematologic responses
were evaluated, along with post-transplant survival and
TRM. Progression-free survival (PFS) and (OS) were deter-
mined using the Kaplan-Meier method.
Results: Of the patients transplanted, 13 were female and 16
weremale.Median age at aHSCTwas 56 (range 26-71). Eleven
(38%) had involvement of at least 2 organs. Median brain
natriuretic peptide and troponin available in 20 patientswere
109 pm/ml (range 24-502) and 0.02ng/ml (range 0.01-1.17).
Twenty-onepatients (72%) receivedhighdoseMelphalan 200
mg/m2. Median CD34+ infused stem cells was 5.00 x 106/kg.
No patients received ﬁlgrastim or other colony stimulating
factor. Time to neutrophil and platelet engraftment were 12
and 17 days, respectively. Three months hematologic
response was available in 22 patients and showed complete
response, partial response, and stable disease in 15(68%), 2
(10%) and 5(22%), respectively. The 1, 3, and 5 year PFS were
78%, 68% and 41%, respectively. One, 3, and 5 year OS from
diagnosis and fromaHSCTwere81, 66, and66%and89, 66 and
66% respectively (Table 1). The 100-day and 1 year TRMwere
3.4% (1 patient) and 6.9% (2 patients), respectively.
Conclusion: Our results show that autologous HSCT is
a reasonable option for patients with newly diagnosed AL
amyloidosis. The 100 day and 1 year TRM compares favorably
to multiple myeloma patients undergoing autologous HSCT.146
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The aim of this prospective, multicenter Phase IIa study
was to investigate whether daily intravenous busulfan (IV
Bu) with bortezomib is a safe and effective conditioning
regimen prior to second, salvage autologous hematopoietic
stem cell transplantation (ASCT) for relapsed multiple
myeloma (MM) patients.
Thirty patients with relapsed MM were enrolled at 11
centers in the US and Canada. Median age at second ASCTwas
59years (range:48-73).Median time fromﬁrstASCT to second
ASCT was 28.0 months (range: 12-119). At the time of second
ASCT, 7 (23.3%) patients were in very good partial response
(VGPR), 12 (40.0%) in partial response (PR), 2 (6.7%) in stable
disease (SD), and 9 (30.0%) in progressive disease (PD).
Patients received a test IV Bu dose (0.8mg/kg) over 2 hours
between Days -12 and -9. The test PK dosing was based on
adjusted ideal body weight (AIBW¼ ideal BW + 0.25 [actual
BWe ideal BW]) for all patients except for thosewhose actual
BW is less than or equal to the ideal BW. For those subjects,
actual BW was used. Pharmacokinetic (PK) analysis deter-
mined Bu exposure as area under the concentration-time
curve (AUC), and provided optimized doses so that a total
target AUC would achieve 20,000 mMmin. These optimized
doseswere administered over 3 hours, once daily fromDay -5
toDay -2. Conﬁrmatory PKwas conducted onDay -5; Bu doses
were furtheradjustedonDays -3and-2, if needed.Bortezomib
(1.3 mg/m2) was intravenously administered on Day -1.
The most common grade 3 or 4 adverse events (CTCAE
v3.0) were febrile neutropenia (50.0%), stomatitis (43.3%),
and nausea (13.3%). One transplant-related death occurred
due to pulmonary complications in a patient with Parkin-
son's disease on Day 20. There were no reported instances of
seizure, worsening neuropathy, or hepatic veno-occlusive
disease meeting the Baltimore criteria.
Post-transplant disease response using the 2006 IMWG
criteriawas available for 28 patients. At 3months, therewere
2 (6.7%) CR, 5 (16.7%) VGPR, 4 (13.3%) PR, 8 (26.7%) SD, and 9
(30.0%) PD. At 6 months, there was 1 (3.3%) stringent CR, 1
(3.3%) CR, 4 (13.3%) VGPR, 7 (23.3%) SD, and 14 (46.7%) PD.
Median progression-free survival was 191 days, while
median overall survival was not reached.
Test PK showed that 40.0% (n¼12/30) of patients had AUC
<1,000 (n¼11) and AUC >1,500 mM*min (n¼1). If body
weight-based doses had been used without test PK, these
patients (40%) would have been dosed outside the target
total AUC range (>24,000 or < 16, 000 mM*min) for condi-
tioning. The conﬁrmatory PK on Day -5 revealed that a total
AUC fell within the target range in 28 patients (93.3%), while
two (6.7%) needed dose reduction on Days -3 and -2.
In conclusion, a combination of IV Bu and bortezomib prior
to second ASCT had acceptable safety proﬁle and induced
20% VGPR or better responses at 6 months. No cases of VOD
were observed in this group of patients in whom dose opti-
mization using pre-transplant test PK was utilized.147
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Delayed engraftment following high-dose chemotherapy
and autologous peripheral stem cell transplantation is a rare
event. Here, we report two cases of delayed engraftment
following autologous peripheral blood stem cell transplant
(PBSCT) for Multiple Myeloma (MM) associated with early
recovery of polyclonal lymphocytes and response to steroids.
Bothof our patientswere 51years oldat timeof transplant and
women. The preparative regimen consisted of Melphalan
200mg/m2 prior to stem cell infusion; the stem cell doses
were between 2.5 and 2.8 million per kilogram. Per protocol,
each received growth factor beginning at day 5 post-trans-
plant. Both patients demonstrated a relative increase in their
peripheral blood lymphocyte count without neutrophil
recoverybyday15 inonepatientandday25post-transplant in
theother. Peripheralblood forﬂowcytometrywasnegative for
lymphoproliferative disorder or recurrence of their disease.
However, it was noted that their CD4:CD8 ratio was 1:6.5 and
1:6.3 with marked increase in CD8 lymphoctyes. This expan-
sion of CD8+ cells has been implicated in autoimmune cyto-
penias inpatientswith autoimmunediseases andwas thought
to be the cause of cytopenias in our patients. Given thedelay in
neutrophil recovery, prednisone 1mg/kg was started for
concerns that thepredominantlyCD8polyclonal lymphocytes
were responsible for suppressing hematopoiesis. Within 48-
72 hours of starting steroids, the peripheral blood lympho-
cytes decreased signiﬁcantly, and both patients demonstrated
neutrophil engraftment followed by platelet engraftment in
the subsequent two-week period. Delayed engraftment
following autologous PBSCT is uncommon. Viral infection is
a common etiology, and rarely, lymphoproliferative processes
like large granular lymphocytes (LGL) have been reportedpost
high-dose therapy and autologous PBSCT for MM. In our
patients, no viral cause was found and there was no clonal
lymphocyte population. In conclusion, this is theﬁrst report of
post autologous PBSCT delayed engraftment in association
with apredominantlyCD8polyclonal lymphocytepopulation.
Thisprocesswas readily reversiblewith corticosteroid therapy
and did not necessitate re-transplantation.148
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Background: A recent study showed that ASCT may reverse
kidney failure in one third of multiple myeloma patients,
which can lead to improvement in blood pressure. However,
there is very limited published data studying the impact of
the treatment on blood pressure control.
Methods: We conducted a review of electronic medical
records of 184 patients with established diagnosis of MM
that underwent an ASCT at Karmanos Cancer Institute
between January 1st, 2009 and December 31st, 2010. We
